News
A mixed bag of top-line phase II data prompted stellar stock results for Prokidney Corp. and its chronic kidney disease (CKD) ...
Insightec Ltd. received U.S. FDA approval for use of its Exablate Neuro device to address severe motor symptoms in patients with Parkinson’s disease, offering a new option for patients who have not ...
Representatives of patients’ groups, industry bodies and venture philanthropy funders are calling for a renewal of the U.K. Rare Diseases Framework, to put fresh momentum behind translational research ...
In yet another fail for the Duchenne muscular dystrophy (DMD) field, Taiho Pharmaceutical Co. Ltd.’s pizuglanstat (TAS-205) did not meet the primary endpoint in a phase III trial. The phase III ...
A mixed bag of top-line phase II data prompted stellar stock results for Prokidney Corp. and its chronic kidney disease (CKD) and diabetes therapy, rilparencel. There were statistically significant ...
Cellular atlases and omics studies, such as genomics, transcriptomics and proteomics, have become key tools for identifying the diversity of all the elements that make up the cardiovascular system.
Glucomodicum Oy reported positive results from a clinical study in which its needle-free continuous glucose monitor, Talisman ...
Tickling Wall Street’s already strong interest in the mechanism of action was Aurinia Pharmaceuticals Inc., which June 30 ...
China’s National Medical Products Administration gave the green light to Simcere Pharmaceutical Group Ltd.’s Enzeshu (suvemcitug) for treating recurrent ovarian cancer, fallopian tube cancer, or ...
Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent form of pancreatic cancer and presents a 5-year survival rate of less than 10%. Novel therapies focusing on targeting the tumor ...
Beijing Konruns Pharmaceutical Co. Ltd. has disclosed tyrosine-protein kinase yes (YES1) inhibitors reported to be useful for the treatment of cancer.
Age-related macular degeneration (AMD) is a leading cause of vision loss in older adults. Current treatments mainly address advanced AMD, while early or intermediate stages rely only on micronutrient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results